Modulating the hormonal environment in which endometrial cancers grow could make tumors significantly more sensitive to a new class of drugs known as poly(ADP-ribose) polymerase (PARP) inhibitors, according to new research.
Critical insights into how melanoma tumors resist BRAF inhibitors were gained from two back-to-back studies. Two key areas are the cell-signaling pathways BRAF-mutant melanoma cells use to become resistant to inhibitor drugs and to evolve and develop drug resistance.
Data from The Cancer Genome Atlas categorizes colorectal cancers and paves the way for the development of targeted therapies.
A new study is using genomic sequencing to develop customized treatments for men with castration-resistant prostate cancer.
An inherited gene variation has been linked to a nearly fourfold increased risk of developing a pediatric acute lymphoblastic leukemia subtype that is associated with a poor outcome.
Researchers have isolated and characterized the progenitor cells that give rise to malignant hepatocellular carcinoma tumors long before the actual tumors can be detected.
Both treatment and survival are improved when a tumor whose primary site is unknown has its molecular profile identified.
When 96 pilocytic astrocytomas were analyzed by whole-genome sequencing, all had MAPK-pathway alterations. This indicates that pilocytic astrocytoma is predominantly a single-pathway disease.
Lung cancer in women who have never smoked is more frequently associated with EGFR mutations and estrogen receptor overexpression, according to a new study.
A group of patients with early-stage, invasive breast cancer who do not benefit from neoadjuvant chemotherapy have been identified by molecular subtyping.
The Cancer Genome Atlas has the potential to generate unprecedented amounts of data on the major cancers and subtypes of cancer.
Improved understanding of how to integrate the results into the treatment planning process is changing the course of treatment for some patients.
Next generation genomic analysis has determined that some of the more aggressive prostate cancers have similar genetic origins, according to a recent publication
Four newly identified genetic variants are associated with an increased risk of testicular cancer, according to a new study that examined the genomes of over 13,000 men.
Findings from a new genome study could enhance current pathology methods in endometrial cancer and help discern types of endometrial tumors.
Sequencing of 57 prostate cancer genomes found that cancer gains a powerful advantage with abrupt intervals of complex, large-scale DNA reshuffling. This process has been dubbed punctuated cancer evolution.
This activity from myCME offers a review of groundbreaking molecular research and novel treatment options for patients with NSCLC.
Is CYP2D6 genotyping for tamoxifen (Nolvadex) sensitivity before use of the drug beneficial?
Mutations in four genes never before associated with colorectal cancer have been found to raise a person's risk for the disease by up to 40%.
A new position statement from the Oncology Nursing Society urges oncology nurses to incorporate new genomic information into practice and patient education.
A new study demonstrated the existence of new fragile genomic sites responsible for chromosomal alterations in tumors.
Large-scale genomic sequencing has revealed two DNA mutations that appear to drive about 15% of brain tumors known as meningiomas.
A novel genetic anomaly was identified in a 44-year-old woman with solitary fibrous tumor. This anomaly provides an important clue to improving how this cancer is diagnosed and treated.
Abnormal epigenetic changes can change the expression of genes. Researchers hope to control the harmful epigenomic changes to turn down cancer itself or perhaps sensitize cancers to existing drugs.
T-cell acute lymphoblastic leukemia (T-ALL) in adults has significantly more mutations than does T-ALL in children, scientists have discovered.
The definition of hormone-sensitive breast tumors known as luminals has been changed by a recent study.
The latest generation of genomic tests for breast cancer can improve physicians' ability to diagnose the disease and more precisely tailor each patient's treatment. This study examined the first commercially available genomic tests.
The American Society of Clinical Oncology has released a nearly 100-page report detailing the year's most significant developments in cancer.
A previously invincible mutation in chronic myeloid leukemia has been thwarted by the investigational drug, ponatinib, in a phase I clinical trial.
The ability to detect cancer DNA in the blood has been combined with genome sequencing technology in a test that could be used to screen for cancers, monitor cancer patients for recurrence, and find residual cancer left after surgery.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|